MAPT and Alzheimer disease: In addition, sTREM2 was found to be increased in patients at early symptomatic stages of AD and correlated well with levels of phosphorylated tau in patients with tau pathology (Rauchmann et al., 2019; Suárez-Calvet et al., 2016).